Apellis Pharmaceuticals Will Commence APL-9 Program to Control the Complement System in Host Responses to AAV Vector Administration for Gene Therapies
CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease
Apellis Pharmaceuticals Completes Enrollment of Phase 3 APL-2 (pegcetacoplan) Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab
Top-line Data Anticipated in December 2019 CRESTWOOD, Ky. and WALTHAM Mass., June 27, 2019 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused
NodThera Highlights Significant Progress with Advancement of Lead Development Candidate and Key Additions to Board
Company advances NT-0167 as first development candidate from a broad platform of NLRP3 inflammasome inhibitors Appoints Don Nicholson as Board Chairman and Kevin Lee as
IGEM Therapeutics Appoints Dr David Chiswell as a Non-Executive Chairman
Cambridge Antibody Technology co-founder and CEO, Dr Chiswell brings 30 years of biotechnology experience to IGEM’s Board London, 9 April 2019 – IGEM Therapeutics (IGEM),
Enterprise Therapeutics Strengthens Leadership Team, Appoints Amit D. Munshi as Non-Executive Chairman
Appointment brings significant commercial pharma experience as Enterprise Therapeutics’ two lead respiratory programmes are progressed towards the clinic Brighton, UK: Enterprise Therapeutics Ltd (Enterprise), a
Epidarex Capital Continues Expansion of its Team
Epidarex Capital, a leading early stage life science firm, is delighted to announce the addition of two veteran life science professionals to its transatlantic team.
Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophy
No inflammation observed in ten patients dosed in Phase 1b trial with new intravitreal APL-2 drug product from modified manufacturing process CRESTWOOD, Ky. and WALTHAM,
Apellis Pharmaceuticals Announces Collaboration with SFJ Pharmaceuticals® for APL-2 in Hematologic Indications
Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement Apellis retains